Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 17 May 2021
Biogen hopes Alzheimer’s drug mired in controversy earns FDA nod
13 May 2021 - After scores of failures, regulators are set to rule on aducanumab, which promises to slow dementia. ...
Posted by Michael Wonder on 17 May 2021
Optimising managed access: lessons from the Cancer Drugs Fund
14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in ...
Posted by Michael Wonder on 17 May 2021
TGA weighs over the counter contraceptive pill plan
17 May 2021 - The nation’s medicines regulator is looking at a plan to give Australians more freedom to access ...
Posted by Michael Wonder on 17 May 2021
Adamis Pharmaceuticals resubmits Zimhi new drug application to FDA for the treatment of opioid overdose
17 May 2021 - Adamis Pharmaceuticals today announced that the new drug application was resubmitted to the U.S. FDA for ...
Posted by Michael Wonder on 17 May 2021
EMA publishes agenda for 17-20 May CHMP meeting
17 May 2021 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 17 May 2021
Quality, access, and the use of real world data by payers: where are we now? Where do we want to be in the future?
15 May 2021 - One of the biggest challenges payers face today is determining the value of innovative therapies in diseases ...
Posted by Michael Wonder on 16 May 2021
Make drug companies partners — not adversaries — to expand global COVID-19 vaccine access
14 May 2021 - The Biden administration’s announcement that it would support waiving patent protections for COVID-19 vaccines to help ...
Posted by Michael Wonder on 16 May 2021
Modernising Medicare coverage pathways for prescription digital therapeutics
13 May 2021 - Outpatient visit restrictions imposed in early 2020 due to COVID-19 increased demand for effective virtual health care ...
Posted by Michael Wonder on 15 May 2021
NICE’s Office for Digital Health opens its doors
11 May 2021 - UK cost effectiveness agency NICE has this week officially opened the Office for Digital Health, one ...
Posted by Michael Wonder on 15 May 2021
Apellis announces U.S. FDA approval of Empaveli (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria
14 May 2021 - Empaveli was superior to Soliris for the change from baseline in haemoglobin level at Week 16 in ...
Posted by Michael Wonder on 14 May 2021
‘More reimbursement needed for hepatocellular carcinoma’
14 May 2021 - “Unlike other cancers, hepatocellular carcinoma is mostly diagnosed non-invasively. But this has not been reflected in ...
Posted by Michael Wonder on 14 May 2021
Making cancer treatments affordable today won’t hurt tomorrow’s innovation
12 May 2021 - Congress is about to debate legislation—the Lower Drug Costs Now Act (H.R.3)—that would give Medicare the ...
Posted by Michael Wonder on 14 May 2021
NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosis
14 May 2021 - NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a ...
Posted by Michael Wonder on 14 May 2021
ICER releases draft evidence report on therapies for atopic dermatitis
14 May 2021 - Public comment period now open until 11 June 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 14 May 2021
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
14 May 2021 - NICE recommends pembrolizumab for colorectal cancer patients with rare mutations. ...